Mayne Pharma
Mayne Pharma Group Limited, commonly referred to as Mayne Pharma, is a prominent Australian pharmaceutical company headquartered in Adelaide, South Australia. Founded in 1850, the company has established itself as a key player in the global pharmaceutical industry, focusing on the development and manufacturing of generic and specialty pharmaceuticals. With a strong presence in both the Australian and international markets, Mayne Pharma is renowned for its innovative drug delivery systems and high-quality generic medications. The company’s core offerings include a diverse range of oral and topical formulations, particularly in the areas of oncology, dermatology, and women's health. Mayne Pharma has achieved significant milestones, including strategic acquisitions and partnerships that have bolstered its market position. Its commitment to quality and innovation has earned it a reputation for excellence, making it a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Mayne Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mayne Pharma's score of 16 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mayne Pharma's reported carbon emissions
Mayne Pharma, headquartered in Australia, has reported its greenhouse gas emissions data for the years 2015 and 2016. In 2016, the company had a greenhouse gas (GHG) emissions intensity of approximately 0.0696 kg CO2e per AUD of revenue, while in 2015, this figure was about 0.0955 kg CO2e per AUD of revenue. This indicates a reduction in emissions intensity over the year, reflecting an improvement in operational efficiency or a shift towards more sustainable practices. However, specific absolute emissions data for Scope 1, 2, and 3 are not disclosed, and there are no documented reduction targets or climate pledges from Mayne Pharma. The absence of detailed emissions reporting suggests that the company may still be in the early stages of formalising its climate commitments. As the pharmaceutical industry increasingly focuses on sustainability, Mayne Pharma's ongoing efforts to monitor and potentially reduce its carbon footprint will be crucial in aligning with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mayne Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
